Menu
Search
|

Menu

Close
X

FibroGen Inc FGEN.OQ (NASDAQ Stock Exchange Global Select Market)

40.44 USD
+0.08 (+0.20%)
As of Nov 16
chart
Previous Close 40.36
Open 39.97
Volume 300,590
3m Avg Volume 184,935
Today’s High 40.59
Today’s Low 38.72
52 Week High 68.15
52 Week Low 38.52
Shares Outstanding (mil) 78.97
Market Capitalization (mil) 4,359.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
105
FY17
143
FY16
180
FY15
181
EPS (USD)
FY18
-1.283
FY17
-0.856
FY16
-1.016
FY15
-1.530
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.59
Price to Sales (TTM)
vs sector
36.97
5.69
Price to Book (MRQ)
vs sector
17.03
5.11
Price to Cash Flow (TTM)
vs sector
--
23.52
Total Debt to Equity (MRQ)
vs sector
49.43
15.71
LT Debt to Equity (MRQ)
vs sector
49.43
11.53
Return on Investment (TTM)
vs sector
-28.39
15.05
Return on Equity (TTM)
vs sector
-58.84
16.62

EXECUTIVE LEADERSHIP

Thomas Neff
Chairman of the Board, Chief Executive Officer, Since 1993
Salary: $840,000.00
Bonus: $693,000.00
Pat Cotroneo
Chief Financial Officer, Since 2008
Salary: $453,000.00
Bonus: $249,150.00
K. Peony Yu
Chief Medical Officer, Since 2016
Salary: $525,000.00
Bonus: $393,750.00
Thomas Kearns
Lead Independent Director, Since 2017
Salary: --
Bonus: --
Jeffrey Edwards
Independent Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

409 Illinois St
SAN FRANCISCO   CA   94158-2509

Phone: +1415.9781200

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.

SPONSORED STORIES